Combination Panvac-BCG does not significantly improve outcomes in non–muscle invasive bladder cancer
The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.
The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
“We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and…
“Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the…
“Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel…
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer.
“There is great interest in looking at all these targeted interventions in the earlier stages to lower the burden of care that patients go through…
“The results showed the contemporary Aquablation procedural safety in Japanese men is exceptional in a broad range of prostate sizes along with significant symptom reduction,”…
“This was a very special moment, delivering the news to this patient that his cancer is now undetectable following the treatment with 2 doses of…